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Abstract
Purpose—Heart rate variability biofeedback (HRVB) therapy may be useful in treating the
prominent anxiety features of perinatal depression. We investigated the use of this non-
pharmacologic therapy among women hospitalized with severe perinatal depression.
Methods—Three questionnaires, the State Trait Anxiety Inventory (STAI), Warwick Edinburgh
Mental Well-Being Scale (WEMWBS), and Linear Analog Self Assessment (LASA), were
administered to fifteen women in a specialized inpatient perinatal psychiatry unit. Participants
were also contacted by telephone after discharge to assess continued use of HRVB techniques.
Results—The use of HRVB was associated with an improvement in all three scales. The greatest
improvement (−13.867, p<0.001 and −11.533, p<0.001) was among STAI scores. A majority
(81.9%, n=9) of women surveyed by telephone also reported continued frequent use at least once
per week, and over half (54.6%, n=6) described the use of HRVB techniques as very or extremely
beneficial.
Conclusions—The use of HRVB was associated with statistically significant improvement on
all instrument scores, the greatest of which was STAI scores, and most women reported frequent
continued use of HRVB techniques after discharge. These results suggest that HRVB may be
particularly beneficial in the treatment of the prominent anxiety features of perinatal depression,
both in inpatient and outpatient settings.
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Perinatal depression is defined as the occurrence of a major and/or minor depressive episode
either during pregnancy or within a period of up to twelve months following delivery (Gavin
et al. 2005; Gaynes et al. 2005; O'Hara and Swain 1996; Yonkers et al. 2001). Prevalence
estimates for major and minor depression includes ranges of 8.5 – 11.0% during pregnancy
and 6.5 – 12.9% during the first twelve months postpartum (Gaynes et al. 2005). Risk
factors for perinatal depression include depression before or during pregnancy (Beck 2001;
Milgrom et al. 2008; O'Hara and Swain 1996; Robertson et al. 2004), marital discord (Beck
2001; O'Hara and Swain 1996), poor social support (Beck 2001; Milgrom et al. 2008;
O'Hara and Swain 1996; Robertson et al. 2004), anxiety during pregnancy, life stress, and
unplanned or unwanted pregnancy (Beck 2001; Robertson et al. 2004). Depressed mothers
have been shown to be more likely to discontinue breastfeeding (Dennis and McQueen
2007; Field 2010; McLearn et al. 2006a), have infants with problematic sleep experiences
(Field 2010; Hiscock and Wake 2001), and be less likely to engage with or nurture their
infant (Lovejoy et al. 2000; McLearn et al. 2006a; McLearn et al. 2006b; Stein et al. 1991)
which can further result in impaired neurodevelopment and increased risk for long-term
psychiatric disorders in their offspring (Campbell et al. 2004; Paulson et al. 2006).
Treatment of perinatal depression is particularly challenging due to a lack of definitive
evidence related to drug therapies during pregnancy and/or breastfeeding. Women have
expressed apprehension about potential side effects related to use of antidepressants, and
these concerns may greatly influence medication compliance or willingness to accept
pharmacologic treatment (Dennis and Chung-Lee 2006). While there is limited evidence of
teratogenic effects or adverse postnatal effects from the use of antidepressants during
pregnancy or breastfeeding, respectively, physicians and mothers alike may be hesitant to
initiate or continue pharmacologic treatments (Einarson and Einarson 2005; Malm et al.
2005; Wen et al. 2006).
Concerns about pharmacotherapy coupled with the risk of potential adverse effects of
inadequately treated illness serves as a unique motivation for this patient population to seek
treatment for depression in modalities other than standard medications, despite the fact that
complementary and alternative medicine (CAM) therapies have often been less rigorously
studied. Heart-rate variability biofeedback (HRVB) is a form of CAM therapy that has
shown promise in the treatment of major depressive disorder (Karavidas et al. 2007) and can
also be used in the treatment of perinatal depression. It also has demonstrated efficacy in the
treatment of attention-deficit disorder, headaches, hypertension, temporomandibular
disorders, urinary incontinence, and fibromyalgia (Hassett et al. 2007; Horowitz 2006).
HRVB refers to a process that utilizes instruments that measure and `feed back' information
about physiological activity, therefore enabling an individual to interpret and respond to
these signals for the purposes of improving their own health and well being (Association for
Applied Psychophysiology and Biofeedback Inc. 2011; Barragan Loayza et al. 2011).
Heart rate variability (HRV) refers to oscillations of heart rate around a mean value,
variations in which are due to changes in the autonomic activity (Friedman 2007), and a
growing body of research suggests that depression is associated with alterations in
autonomic function, such as impaired baroreflex sensitivity, changes in heart rate, and
reduced heart rate variability (HRV) (Karavidas et al. 2007). Increases in HRV have been
demonstrated to occur in patients successfully treated with antidepressants' (Balogh et al.
1993), and a review of over twenty studies revealed an association between abnormalities of
HRV and the presence of anxiety (Cohen and Benjamin 2006).
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HRVB may therefore be suited to treat the prominent anxiety features of perinatal
depression. Bernstein, et al. (2008) demonstrated that, compared to non-postpartum
depressed patients, patients with postpartum depression displayed more prominent anxiety-
related symptoms, such as psychomotor restlessness and agitation as well as impaired
concentration and decision-making. Beck and Indman (2005) also revealed that among
women diagnosed with major postpartum depression, one of the top three elevated
dimensions of the Postpartum Depression Screening Scale was anxiety. A Cochrane Review,
published in 2011, showed that there is some evidence that mind-body interventions, such as
autogenic training, biofeedback, hypnotherapy, imagery, meditation, prayer, auto-
suggestion, tai-chi, and yoga, may be beneficial in the treatment of anxiety during pregnancy
(Marc et al. 2011). We therefore hypothesized that among inpatient perinatal psychiatry
patients, the use of adjunctive HRVB treatments would result in a decrease in the prominent
anxiety symptoms that are known to be a central feature of perinatal depression.
MATERIALS AND METHODS
Participants
Patients were recruited from the UNC Hospitals Perinatal Inpatient Psychiatry Unit (PPIU)
from January 31, 2012 – June 1, 2012. Eligible participants were female, over age 18,
English-speaking, currently pregnant or within one year of delivery, and admitted to the
PPIU for treatment of severe depression and/or anxiety. All patients admitted to the PPIU
are offered the opportunity to participate in HRVB therapy with a recreational therapist who
is trained and certified in biofeedback techniques.
Thirty-six patients were admitted to the PPIU during the course of the study, and thirty-one
(86.1%) were eligible for participation. Nine (29%) of the thirty-one patients refused and
seven (22.5%) were admitted for short stays on the unit, which precluded their involvement
in biofeedback therapy. A total of fifteen patients were enrolled. This study that had full
approval from the UNC Institutional Review Board, and all subjects gave informed written
consent for study participation.
Equipment and Technical Procedures
HRVB was administered using the emWave® Desktop (HeartMath®, Boulder Creek,
Colorado) heart-monitoring system (Childre and Martin 1999). The system functions by
using a pulse sensor that is placed on the patient's earlobe and then connected to the
program. The sensor collects information and translates it into graphics that are displayed on
a computer screen. These graphics are used to display heart rhythm patterns in real-time,
which allows patients to receive immediate feedback on their performance.
Patients participating in HRVB therapy were taken to a private room where the instruction
and participation in HRVB therapy was conducted individually. Patients completed two
HRVB therapy sessions, ranging in length from 30 minutes to 1 hour. The initial session
consisted of educating the patient about biofeedback, the science behind the technique, and
potential benefits and outcomes of its use. The patient was then provided with a
demonstration and given time to practice using the skills of biofeedback. Specifically,
patients were trained to use deep, abdominal or diaphragmatic breathing techniques to
disengage from anxious and/or stressful thoughts and emotions. The second session
consisted of administration and practice of HRVB and strategies for utilizing biofeedback
after discharge from the hospital.
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Patients were asked to complete a set of three self-report questionnaires, the State Trait
Anxiety Inventory: State Anxiety Scale, the Linear Analog Self-Assessment and the
Warwick-Edinburgh Mental Well-Being Scale just prior to participation in their first
biofeedback session and again immediately following the session (time point A).
Participants again completed the questionnaires according to the same protocol at the time of
the second biofeedback session (time point B), for a total of four completed sets of
assessments. Additionally, all patients admitted to the inpatient unit are asked to complete an
Edinburgh Postnatal Depression Scale at the time of admission and again prior to discharge.
Lastly, participants were contacted by telephone after discharge to assess continued usage of
HRVB techniques outside of the hospital setting.
Instruments
State Trait Anxiety Inventory: State Anixety Scale (STAI)—The Spielberger State
Anxiety Inventory (STAI) is a widely used, validated twenty-item psychological inventory
based on a four-point Likert scale that measures anxiety in the present moment (Spielberger
1983). Possible scores range from twenty to eighty, and higher scores are correlated with
higher levels of anxiety.
Linear Analog Self-Assessment (LASA)—The Linear Analog Self Assessment
(LASA) is a survey instrument that contains six simple items that assess patients' state of
anxiety and feelings about specific domains of quality of life based on a Likert Scale (Locke
et al. 2007). On this scale, scores range from six to thirty, and higher scores are correlated
with better quality of life.
Warwick-Edinburgh Mental Well-Being Scale (WEMWBS)—The Warwick-
Edinburgh Mental Well-Being Scale (WEMWBS) is a fourteen-item scale with five
potential response categories for each item (Tennant et al. 2007). It assesses patients'
thoughts and feelings over the past two weeks. Similar to the LASA instrument, higher
scores are associated with better well-being. The lowest possible score is fourteen and the
highest possible is seventy.
Edinburgh Postnatal Depression Scale (EPDS)—The EPDS is one of the most
commonly used and validated instruments for assessing perinatal depression (Brouwers et
al. 2001; Cox et al. 1987). A cut-off of score of ≥ 12 on the EPDS has been consistently
shown to be associated with major depression, when compared to a structured clinical
interview (Cox et al. 1987). EPDS scores of 10–12 have been associated with an accurate
diagnosis of minor depression.
Post-Discharge Follow-up Assessment—Participants were also contacted by
telephone approximately six weeks after discharge to assess continued use of biofeedback
techniques. Using a multiple choice, Likert scale survey developed by the authors,
participants were asked how frequently they had used HRVB techniques since their
discharge and how beneficial they found the techniques to be. Lastly, participants were
asked if they had purchased the HeartMath® machine for personal use.
Coherence Scores—The emWave machine measures coherence, which correlates with
improved order and correspondence between an individual's psychological and
physiological processes. Physiologically, this state of coherence is reflected in the presence
of a smooth, sine-wave-like pattern in the HRV tracing. There are three levels of coherence
scores that can be attained using the emWave machine – low, medium, and high. Low
coherence reflects the percentage of time in which there is no wave-like activity; medium
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coherence indicates the percentage of time in which there is some wave-like activity; and
high coherence reflects the percentage of time in which there is a great deal of wave-like
activity in the HRV tracing (HeartMath 2011).
Data Analysis
Our hypothesis for this study was that exposure to HRVB therapy would be associated with
improvements in scores on the three instruments assessing anxiety, quality of life and mental
well-being. Primary outcome measures were differences in pre- versus post-treatment
instrument scores. Statistical analysis was performed using SPSS software, version 19.0
(SPSS, Inc., Chicago, IL). Paired samples t-tests were conducted to compare the difference
in scores of all three instruments used, the STAI, LASA and WEMWBS, between pre- and
post-HRVB therapy sessions. This analysis was conducted for each of the two time points
(A and B) at which participants completed HRVB therapy and the pre- and post-treatment
surveys. The EPDS score, as a potential confounder, was analyzed using fixed effects
regression analysis, in order to determine whether admission EPDS scores had a significant
effect on the size of score difference on each of the three instruments used. A p value of less
than 0.05 was considered statistically significant for all tests.
RESULTS
Demographic characteristics of participants are displayed in Table 1. The average age of
participants was 31, and the majority of participants was Caucasian (86.7%, N=13), married
(80%, N=12), and in the postpartum period (73.3%, N=11). Additionally, coherence score
data is included in Table 2. The data demonstrates that the proportion of coherence scores in
the medium (M = 42.00 – 55.00) to high (62.73 – 65.29) range increased when participants
were actively using HRV techniques compared to the medium (M = 28.30 – 25.58) to high
(M = 6.00 – 16.25) scores at baseline when not using the techniques. This suggests that
participants were correctly utilizing the HRV techniques and achieving a greater state of
physiologic coherence.
The mean time difference between time point A and time point B was 2.2 days, and survey
instruments at both time points showed statistically significant mean differences in pre-
versus post-HRVB treatment scores. There was a significant difference in the scores for the
STAI survey, when comparing pre- versus post-HRVB treatment, at time both point A (M=
−13.867, p<0.001) and at time point B (M=−11.533, p<0.001). Similarly, there was also a
significant difference in the sum scores achieved on the WEMWBS survey at both time
point A (M=6.143, p<0.001) and time point B (M=5.333, p<0.001). Lastly, the difference in
scores on the LASA surveys was also significant, both at time point A (M=1.933, p=0.024)
and time point B (M=2.867, p<0.001). These results suggest that biofeedback treatment
sessions had a positive effect on the sum scores on each of the three surveys completed by
participants, as there was a statistically significant improvement across all instruments in
pre- versus post-therapy scores at both time points. Given that a higher score on the STAI
instrument is associated with increased levels of anxiety, a score decrease is therefore
associated with reduced levels of anxiety. Conversely, the WEMWBS and LASA instrument
scores are proportional to levels of mental well-being and quality of life, respectively.
Therefore, a positive change in these scores likely reflects an improvement in these two
measures. Further details of this analysis are included in Table 3.
The admission EPDS score had no statistically significant effect on STAI scores at time
point A (p=0.106) or at time point B (p=0.185), nor did it significantly affect the difference
in WEMWBS scores at time point B (p=0.104). The EPDS scores did have a statistically
significant effect on LASA scores at both time points A (p=0.003) and B (p=0.029) as well
as on WEMWBS scores at time point A (p=0.002). These results suggest that each one point
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increase in EPDS score corresponds to a 0.440706 (point A) and 0.327996 (point B) point
decrease in the LASA score differences. Similarly, each one-point increase in EPDS score
also corresponds to a 1.377832 decrease in the WEMWBS score difference at time point A.
These results are summarized in Table 4.
Of the fifteen participants enrolled in the study, eleven (73.3%) completed the continued use
phone survey, the results of which are displayed in Table 5. A majority of respondents
(81.9%, N=9) reported using the techniques at least once per week, if not more frequently,
and more than half (54.6%, N=6) rated biofeedback techniques as either very or extremely
beneficial. None of the participants surveyed had purchased the HeartMath® machine for
home use.
DISCUSSION
This study demonstrates that among our participants, scores on all three instruments
improved after women were exposed to HRVB therapy. While all three scores improved, the
largest differences were observed among the STAI scores, with mean differences of 11.533
and 13.867, compared to mean differences in WEMWBS scores of 6.143 and 5.333 and in
LASA scores of 1.933 and 2.867. Biofeedback techniques have previously been
demonstrated to improve STAI scores in work done by Siepmann, et al. (2008), which
showed a median 20-point reduction in STAI scores among male and female participants
undergoing biofeedback therapy for the treatment of depression.
The greatest difference was seen in comparing pre- versus post-treatment STAI scores, and
therefore our results suggest that HRVB was most beneficial in targeting the acute anxiety
symptoms of perinatal depression. Given that all patients hospitalized on the PPIU receive a
full range of traditional treatments, including medications and psychotherapy, as well as the
use of other CAM therapies such as yoga, we did not attempt to analyze improvements in
instrument scores over the course of the inpatient stay, as it would be difficult to isolate the
individual effects of the various treatments that the patients receive.
Our results suggest that admission EPDS scores did have some effect on the mean
differences in pre- and post-treatment LASA scores at both time points and WEMWBS
scores at time point A. This suggests that women with more severe depression may have
experienced a slightly reduced benefit from participating in HRVB therapy. While these
effects were statistically significant, they were small in magnitude; all resulting in less than a
1.5-point decrease in mean score difference in these two instruments. Additionally,
admission EPDS scores, and therefore depression severity, did not seem to have a significant
effect on mean differences in STAI scores at either time point.
Improvement in anxiety symptoms is of great importance in the treatment of this patient
population, given that anxiety seems to be a prominent feature of their illness. As previously
noted, there is evidence to suggest that anxiety may play an even greater role among women
with postpartum depression. Hendrick et al. (2000) showed that among women seeking
treatment for major depression, postpartum depressed women were more likely to present
with anxious features compared with depressed women not in the postpartum period.
Similarly, Ross, et al. (2003) showed that among pregnant and postpartum women who
screened positive for depression on the EPDS, the 3-item anxiety subscale accounted for
47% of the total score among women in pregnancy and 38% of the total score among
postpartum women.
Furthermore, the patients included in this study were particularly ill, with depression
severity requiring hospital admission. The literature documents that perinatal depression
presents with prominent anxiety features (Bernstein et al. 2008), and therefore, an
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intervention that focuses on management of anxiety is particularly important in those
patients who require inpatient hospitalization. HRVB seems to, therefore, have a promising
role in both inpatient as well as outpatient management of perinatal depression, the potential
of which is further emphasized by the results of the follow-up telephone survey.
In addition to the demonstrated improvements in scores on the standardized instruments,
participants in the study seemed to also perceive a benefit from utilizing biofeedback
techniques, even outside of the hospital setting. A majority of participants (81.9%) who
were surveyed about continued use reported using biofeedback techniques at least once per
week, and a majority (54.6%) of participants also rated the use of biofeedback as either very
or extremely beneficial to them in the outpatient setting. These results were obtained in the
setting of none of the respondents having purchased the HeartMath® machine for personal
use, indicating that they were able to practice HRVB techniques without the use of
additional equipment.
While the results of this study are promising, it nevertheless is not without limitations. First
of all, this study is limited by the absence of a control group against which to compare
outcomes. Without a control group, it is difficult to say with certainty that the improvements
in instrument scores are attributable to the usage of HRVB rather than regression to the
mean or effects of passage of time. The study also includes a small, somewhat homogeneous
sample size of fifteen, mostly Caucasian participants. Although HRVB treatment sessions
were conducted in a similar manner and led by a single therapist, variations in participants'
abilities and performance were not accounted for in this study. While the results suggest that
the use of HRVB may have more immediate, short-term benefits for women with perinatal
depression, this study did not assess potential long-term effects of it use. Lastly, while
participants generally reported frequent use and significant perceived benefit from using
HRVB techniques after discharge, it is possible that because this survey was conducted via
telephone, that responses were affected by social desirability bias, causing participants to
report increased frequency or benefit of use.
CONCLUSION
Biofeedback may have a promising role as a complementary treatment for perinatal
depression. While it may be effective in treating all forms of major depression, it seems to
be particularly useful among this patient population. Given the heightened concern about
potential adverse effects of pharmacologic treatments on a developing fetus or a newborn
that is breastfeeding, additional non-pharmacologic treatments are greatly needed for
pregnant and postpartum women with depression. Our study demonstrated that HRVB may
be particularly effective in treating the prominent anxiety symptoms of perinatal depression,
as evidenced by the significant reduction in STAI scores. This effect may be greatly useful
among pregnant and postpartum women, whose depression tends to be associated with
significant anxiety features. Lastly, the utility of HRVB techniques seems to also be
valuable to patients in the outpatient setting, as evidenced by their reported continued use
and perceived benefits of doing so. While this study shows promising results, further
research is needed among a larger, more diverse population and in comparison with a
control group to better assess the use of biofeedback in the treatment of perinatal depression.
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Table 1
Demographic Characteristics of Participants
Characteristics Overall Mean (Range) or Frequency (Percent)
Age 30.8 (19–42)
Race (n=15)
 White/Caucasian 13 (86.7%)
 African American 2 (13.3%)
 Hispanic 0
Marital Status (n= 15)
 Single 0
 In a relationship 3 (20%)
 Married 12 (80%)
 Separated/divorced 0
 Widowed 0
Highest Level of Education Completed (n= 15)
 Some high school 1 (6.7%)
 High school diploma 1 (6.7%)
 Some college 3 (20%)
 Two-year college program 3 (20%)
 Four-year college/Bachelor's degree 2 (13.3%)
 Graduate school 5 (33.3%)
Pregnancy Status
 Currently pregnant 4 (26.7%)
 Postpartum 11 (73.3%)
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Table 2




Baseline 80.73 28.30 6.00
Active 23.33 55 65.29
Time Point B
Baseline 75.2 25.58 16.25
Active 34.75 42 62.73
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Table 4
Fixed Effects Regression Analysis of Admission EPDS Scores and Survey Score Differences
Score Difference Time Point Estimate p-value
STAI A 0.70491 0.106
B 0.630786 0.185
WEMWBS A −1.377832 0.002
B −0.654241 0.104
LASA A −0.440706 0.003
B −0.327996 0.029
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Table 5
Continued Use Phone Survey Results
Question Overall Frequency (Percent) Overall Mean (Range)
Frequency of use (n=11)
 Not at all 1 (9.1%) 3.36 (1–6)
 Once per month 1(9.1%)
 Once per week 4 (36.4%)
 More man once per week 4 (36.4%)
 Once per day 0 (0.0%)
 More man once per day 1 (9.1%)
Benefit of use (n=10)
 Not at all beneficial 0 (0.0%) 3.55 (2–5)
 Somewhat beneficial 1 (9.1%)
 Moderately beneficial 4 (36.4%)
 Very beneficial 5 (45.5%)
 Extremely beneficial 1 (9.1%)
Purchase of HeartMath machine for home use 2.00 (2–2)
 Yes 0 (0.0%)
 No 11 (100.0%)
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